BiPar At The Center Of Sanofi's Efforts To Rebuild Its Oncology Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III PARP inhibitor for triple-negative breast cancer leads Sanofi's efforts to restock its oncology pipeline.